SCM
PCRX icon

Shelton Capital Management’s Pacira BioSciences PCRX Stock Holding History

Shelton Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,858
Closed -$218K – 783
2022
Q1 		$218K Buy
+2,858
New +$191K 0.01% 737
2021
Q2 		– Sell
-2,858
Closed -$200K – 852
2021
Q1 		$200K Buy
+2,858
New +$204K 0.01% 784

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Shelton Capital Management's PCRX Position: Q2 2022 in Review

Shelton Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 2,858 shares — an estimated $218K sold.

Shelton Capital Management first reported a position in PCRX in Q1 2021 and held it in 2 quarters. The position peaked at $218K in Q1 2022. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

  • Shelton Capital Management reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
  • Shelton Capital Management sold 2,858 Pacira BioSciences shares in Q2 2022, an estimated $218K.
  • Shelton Capital Management first reported a position in Pacira BioSciences in Q1 2021 and held it in 2 quarters.
  • Shelton Capital Management's Pacira BioSciences position peaked at $218K in Q1 2022.
  • 284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on Shelton Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.